Complete Remission in a Patient with Human Herpes Virus-8 Negative Multicentric Castleman Disease Using CHOP Chemotherapy I n t r o d u c t i o n
Castleman disease (CD) is a rare lymphoproliferative disorder diagnosed by clinical, histopathologic, and laboratory criteria. The disease was first described as a pathologic entity in 1954 and was defined in 1956 (1) . The two primary clinical presentations are unicentric (UCD) and multicentric CD (MCD). The disease is confined to a single lymph node with UCD, while MCD typically presents with lymphoid hyperplasia at multiple sites, including the peripheral lymph nodes, bone marrow, and multiple organs.
Pathology is associated with systemic signs and constitutional symptoms. CD is classified into three histological subtypes: 1) hyaline-vascular CD, 2) plasma cell CD, and 3) mixed variant CD. Hyaline-vascular CD is characterized by numerous germinal follicles in the lymph nodes with thick-walled blood vessels and a concentrically expanded follicular mantle zone. These result in a characteristic onion peel appearance. Plasma cell CD is characterized by large, hyperplastic follicles with intervening sheets of plasma cells (2) , and results in fever, sweats, fatigue, anemia, polyclonal hypergammaglobulinemia, and bone marrow plasmacytosis. Hyaline-vascular CD is identified in approximately Mycobacterium infection. Histologic evaluation of a lymph node biopsy from the left axilla yielded a diagnosis of MCD. Cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) were administered for a total of 4 cycles. The patient's fever and lymphadenopathy resolved after the course of chemotherapy. She has been in complete remission for 24 months at this writing. As previously reported, this case report suggests that MCD can develop without viral infection. CHOP chemotherapy may be an effective treatment option for newly diagnosed MCD patients.
90% of patients with unicentric CD (3). Conversely, most MCD cases are of the plasma cell predominance type. Mixed CD forms also exist with both hyaline-vascular and plasma cell elements.
Immunologic pathogenic processes have been implicated in MCD, and viral infections may be involved in disease pathogenesis. Recent reports have identified CD cases without viral infection (4, 5) . This case report describes a multicentric Castleman disease patient without HHV-8 and HIV infection. The patient was successfully treated with combined chemotherapy.
C a s e R e p o r t
A 43-year-old female patient presented to our hospital in January 2005 for evaluation of 6 months' duration of fever (38 ) (Fig. 1) . Concentrated urine protein electrophoresis revealed polyclonal hypergammaglobuminemia (15.8 mg/dL). Plasma cell MCD was diagnosed by histologic evaluation of a left axillary lymph node biopsy (Fig. 2, 3) . There was no evidence of bone marrow involvement. The patient tested negative for HHV-8, HIV, Mycoplasma, Salmonella, Legionella, and Mycobacterium infections (Fig. 4) . CHOP chemotherapy consisted of intravenous (IV) cyclophosphamide (750 mg/m 2 on day 1), IV adriamycin (50 mg/m 2 on day 1), IV vincristine (1.4 mg/m 2 on day 1), and oral prednisone (100 mg for 5 days) was administered every 3 weeks for 4 cycles. The patient's fever subsided and her lymphadenopathy resolved after the initial course of treatment (Fig. 5) . At this writing, the patient has been in complete remission for 24 months.
Fig. 2. Left axillary lymph node biopsy. (A) Heavy infiltration of plasma cells and occasional eosinophils in the medullary cords and interfollicular areas (H & E, 400). (B)
Plasma cells were strongly reactive for Vs38, and some cells were large and multinucleated (Vs38 Immunohistochemical stain, 400). 
D i s c u s s i o n
Multicentric CD was clinico-pathologically defined in 1983 (6). CD is a lymphoproliferative disorder characterized by both systemic lymphadenopathy and polyclonal hypergammaglobulinemia with possible constitutional symptoms. However, the etiology of CD is poorly understood. Various immunopathologic processes have been suggested and the best therapeutic options are not well-established.
HHV-8 is a gamma herpesvirus that was initially identified in Kaposi sarcoma patients. It is frequently present in acquired immunodeficiency syndrome (AIDS)-associated Kaposi sarcoma (7). HHV-8 DNA is frequently detected in the peripheral blood of HIV-positive patients with MCD (8). However, HHV-8 DNA is detected in 41% of HIV-negative MCD patients, and HHV-8 is associated with MCD etiology. HHV-8 has a viral homologue of human interleukin (IL)-6 in its genomic DNA, and this has been suggested that HHV-8 infection may be related to excessive IL-6 production. IL-6 overproduction in HHV-8-infected lymphocytes has been postulated as a pathogenic MCD cause. Increased serum IL-6 was reported in many MCD patients, and IL-6 may have linked plasma cell proliferation and vessels in CD (9) . There are multiple etiologies for the promotion of IL-6 overproduction. In addition, increases in cytokines including IL-1 and tumor necrosis factor (TNF)-are possibly associated with CD. Vascular endothelial growth factor (VEGF) levels in the sera and supernatants of cultured lymph nodes from CD patients were higher than in normal controls (10) . This suggested that VEGF may be involved in CD pathogenesis. The immune stimulus for HHV-8 negative MCD is not established.
The standard treatment option for CD remains uncertain. However, treatment options include surgical excision, cytoreductive chemotherapy, and radiation therapy. Patients with unicentric disease can be cured by surgery, although radiotherapy is another option for poor surgical candidates. MCD patients must undergo comprehensive laboratory testing, including a complete blood count, C-reactive protein levels, liver function tests, anti-nuclear antibody titers, rheumatoid factor levels, HIV screening, IL-6 levels, HHV-8 testing, and CD20 levels. Several antiviral medications (ganciclovir, valganciclovir, foscarnet, and cidofovir) have resulted in mixed responses for the inhibition of HHV-8 replication in HHV-8-associated MCD patients (11) . Recent reports have suggested that rituximab may serve as an option for CD20-expressing MCD patients (4, 12) . Rituximab is a monoclonal antibody against CD20, and is primarily used to treat non-Hodgkins lymphoma patients. Other immune modulator treatment modalities include steroids, interferon-, all-trans retinoic acid, and thalidomide, none of which have resulted in consistent disease control (13) . Chemotherapy is the first treatment option in most progressive or symptomatic patients. Both single and multiple agent combination chemotherapy have been effectively used in MCD treatment. Chlorambucil, cyclophosphamide, vinblastine, and etoposide have demonstrated efficacy and are well-tolerated in some patient (14, 15) . Cytoreductive combination chemotherapies, including CHOP or CVP (cyclophosphamide, vincristine, and prednisone), have been effectively used in immunocompetent non-Hodgkins lymphoma patients (14) . These may be suitable for MCD patients. These treatments may be associated with marked toxicity in HIV-positive patients, so patients must be carefully selected and closely monitored for infection.
In conclusion, our case suggests that MCD can develop without evidence of a viral infection. CHOP chemotherapy may be an effective first-line therapy for newly diagnosed MCD patients.
